<DOC>
	<DOCNO>NCT00619502</DOCNO>
	<brief_summary>This follow-up Study A3L10 ( NCT00315055 ) Immunogenicity - To describe antibody persistence follow primary series vaccination either DTaP-IPV-HB-PRP~T PENTAXIM™ ENGERIX B® . - To describe immunogenicity booster dose DTaP-IPV-HB-PRP~T . Safety - To describe safety profile booster dose DTaP-IPV-HB-PRP~T .</brief_summary>
	<brief_title>Study Immunogenicity Safety Booster Dose DTaP-IPV-HB-PRP~T Combined Vaccine Healthy Turkish Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Toddler previously include Study A3L10 complete threedose primary series vaccination either DTaPIPVHBPRP~T PENTAXIM™ ENGERIX B® 2 , 3 4 month age . Toddler 15 18 month age ( range : 456 578 day age inclusive ) . Informed Consent Form sign parent ( ) legal representative ( ) institution official Investigator . Able attend schedule visit comply trial procedure . Participation another clinical trial 4 week precede booster vaccination . Planned participation another clinical trial present trial period . Congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy . Systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance . Chronic illness stage could interfere trial conduct completion . Blood bloodderived product receive last 3 month . Any vaccination 4 week precede booster vaccination . Any vaccination plan second Visit . History document pertussis , tetanus , diphtheria , polio , Haemophilus influenzae type b hepatitis B infection ( ) ( confirm either clinically , serologically microbiologically ) . Previous booster vaccination pertussis , tetanus , diphtheria , polio Haemophilus influenzae type b , hepatitis B infection ( ) . Coagulopathy , thrombocytopenia bleed disorder contraindicate intramuscular vaccination . Any vaccinerelated serious adverse event occur follow threedose primary series administration investigational vaccine reference vaccine Study A3L10 ( NCT00315055 ) . Febrile ( temperature ≥ 38.0°C ) acute illness day inclusion . Known contraindication vaccination pertussis vaccine , i.e . : Encephalopathy ; temperature &gt; 40.0°C within 48 hour follow vaccine injection , due another identifiable cause primary series ; Inconsolable cry occur &gt; 3 hour within 48 hour follow vaccine injection primary series ; Hypotonic hyporesponsive episode within 48 hour follow vaccine injection primary series ; Seizures without fever within 3 day follow vaccine injection .</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Polio</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Pertussis</keyword>
	<keyword>H.influenzae type b</keyword>
</DOC>